Given the high prevalence of expression of both Mer and Flt3 and the data indicating their oncogenic roles in AML, targeting them together is an attractive therapeutic strategy, and could potentially result in better outcomes in high-risk patients, reduced need for chemotherapy in low-risk patients, or a therapeutic option for those who cannot tolerate high-intensity chemotherapy. This evidence concerns the gene FLT3 and acute myeloid leukemia.